Dr. Birner

Biography

Dr. Birner is Managing Partner at TVM Capital’s Munich and Montreal offices. He is responsible for numerous active investments in Europe as well as the United States. He currently serves as chairman of the board of AL-S Pharma (Zürich, Switzerland), Argos Therapeutics Inc. (Durham, North Carolina), leon-nanodrugs GmbH (Munich, Germany) and Spepharm Holdings BV (Amsterdam, The Netherlands) and is a member of the board of directors of Proteon Therapeutics, Inc. (Boston, Massachusetts). Over many years, he was the chairman/vice chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany), which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd., respectively. Before joining TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Hubert joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant, he gained extensive experience in management in research and development, marketing and sales, joint venture structuring and business development. Dr. Birner was also an assistant professor for biochemistry at the Ludwig-Maximilians-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. He holds an MBA from Harvard Business School and a doctoral degree in biochemistry from Ludwig-Maximilians-University Munich, where he graduated summa cum laude. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. 

Research Interest

 Biochemistry and business administration.